我要投票 来利Larlly在减肥药行业中的票数:338
· 外 推 电 报 ·
2025-04-26 17:26:04 星期六

【来利Larlly是哪个国家的品牌?】

来利Larlly,专业减肥药品牌,安全、健康品牌。 浙江海正药业股份有限公司,创建于1956年,为国有控股上市公司,总部位于浙江省台州市,现有员工9000多人,2000年7月“海正药业”A股在上海证券

外推网助力来利Larlly品牌出海!通过在本页面挂载来利Larlly品牌的产品链接和联系方式,可以提高来利Larlly产品曝光!跨境电商爆单神器,目前只要100元/年哦~

来利Larlly,专业减肥药品牌,安全、健康品牌。

浙江海正药业股份有限公司,创建于1956年,为国有控股上市公司,总部位于浙江省台州市,现有员工9000多人,2000年7月“海正药业”A股在上海证券交易所上市(股票代码:600267)。海正先后获得“国家高新技术企业”、国家首批“创新型企业”、“技术创新示范企业”、“国家知识产权试点企业”、“药品出口示范基地”、全国五一劳动奖状等称号,还多次荣获“出口型企业品牌十强”、“创新型企业品牌十强”和“全国制造业500强”。2014年,荣登财富中国500强排行榜入围浙江省首批“三名”企业名单。“海正”、“HISUN”和被认定为驰名保护,并圆满完成了“抗甲流药物达菲关键中间体——环氧化物生产”国家任务,受到国务院和有关部委的表扬、省政府的单独表彰。

海正在浙江台州、杭州以及江苏如东等地区建有一体化制药基地,主营抗肿瘤、抗感染、心血管、内分泌、免疫抑制、抗抑郁、骨科等领域的原料药、制剂的研产销业务,业务遍及全球70多个国家和地区。2014年,海正药业销售收入超过100亿元。

海正建有国家认定的企业技术中心和博士后科研工作站,在北京、上海等地分别建有研发机构。每年研发投入占工业销售收入8%以上,研发人员近1200人,其中国家“千人计划”8人,省“千人计划”19人,形成了以国内科学家为主体,欧美、日本、俄罗斯等国的多名国外科学家组成的基因工程药物、微生物药物、合成药物、制剂、新药筛选等领域的科研创新人才团队。同时,围绕“生物药、化学药”两大领域开展自主品牌新药创制,与国内30所大学、研究院所产学研结合,联盟化发展,在特色原料药产业化和高端制剂产业化等形成了特色和优势。

海正积极推进民族医药创新和国际化进程,实施“五大转型”,不断推进原料制剂一体化、制剂品牌化和生物产业化,已从单纯的产品出口、贸易伙伴发展成为与国际大公司建立战略联盟,从单一的原料药出口发展为原料药与自主品牌制剂同步,从为国外大公司定制生产发展为共同创新研发。



英文翻译:Larlly, a professional weight-loss drug brand, is a safe and healthy brand. Zhejiang Haizheng Pharmaceutical Co., Ltd., founded in 1956, is a state-owned holding listed company with its headquarters in Taizhou City, Zhejiang Province. It has more than 9000 employees. In July 2000, "Haizheng pharmaceutical" a share was listed on the Shanghai Stock Exchange (Stock Code: 600267). Haizheng has successively won the titles of "national high and new technology enterprise", the first batch of "innovative enterprise", "technological innovation demonstration enterprise", "national intellectual property pilot enterprise", "drug export demonstration base", National May 1st Labor Medal, etc., and has also won "top 10 export-oriented enterprise brands", "top 10 innovative enterprise brands" and "top 500 national manufacturing industry" for many times. In 2014, it was listed as one of the first "three" enterprises in Zhejiang Province. "Haizheng" and "Hisun" have been recognized as well-known protection, and successfully completed the national task of "production of epoxide, a key intermediate of Tamiflu, an anti H1N1 drug", which has been praised by the State Council and relevant ministries and commissions, as well as the provincial government. Haizheng is building an integrated pharmaceutical base in Taizhou, Hangzhou, Zhejiang Province and Rudong, Jiangsu Province. It is mainly engaged in the research, production and marketing of raw materials and preparations in the fields of anti-tumor, anti infection, cardiovascular, endocrine, immunosuppression, anti depression, orthopedics, etc. its business covers more than 70 countries and regions in the world. In 2014, the sales revenue of Haizheng pharmaceutical exceeded 10 billion yuan. Haizheng has established enterprise technology centers and postdoctoral research stations recognized by the state, and R & D institutions in Beijing, Shanghai and other places. The annual R & D investment accounts for more than 8% of the industrial sales revenue, with nearly 1200 R & D personnel, including 8 in the national "thousand talents plan" and 19 in the provincial "thousand talents plan", forming a scientific research innovator in the fields of genetic engineering drugs, microbial drugs, synthetic drugs, preparations, new drug screening, etc., mainly composed of domestic scientists and many foreign scientists from Europe, America, Japan, Russia and other countries Only team. At the same time, the independent brand new drug creation is carried out around the two major fields of "biological medicine and chemical medicine", combined with the production, teaching and research of 30 universities and research institutes in China, and developed in alliance, forming features and advantages in the industrialization of characteristic APIs and high-end preparations. Haizheng has actively promoted the innovation and internationalization of national medicine, implemented the "five transformations", and continuously promoted the integration of raw materials and preparations, the branding of preparations and the bio industrialization. It has developed from a simple product export and trade partner to a strategic alliance with large international companies. It has developed from a single raw material drug export to a raw material drug and an independent brand preparation. It has developed from a single raw material drug export to a foreign company The development of manufacturing and production is joint innovation and R & D.

本文链接: https://www.waitui.com/brand/91230fb32.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

多家银行发公告警示黄金投资风险,专家:信用卡炒金涉嫌违规

金价高位运行,让黄金投资持续升温。一些人贷款或用信用卡套现买黄金,还在社交媒体分享所谓的“攻略”。多家银行发出公告警示投资风险,并表示严控信用卡“炒金”。专家表示,近期黄金大幅波动,加杠杆追涨黄金,存在巨大的资金风险。此外,专家提醒,我国对贷款和信用卡资金的用途有明确要求,相关资金不得用于黄金投资等领域。(央视网)

2小时前

高盛:3月初以来外国投资者已抛售价值630亿美元的美国股票

随着美国企业业绩前景受到关税政策的影响,资本市场上它们的股票也大量遭到抛售。据美国有线电视新闻网24日报道,早在美国政府刚开始威胁要推出关税政策时,许多投资者就已经开始抛售其手中持有的美国公司股票。报道称,今年第一季度,仅包括 摩根大通首席执行官杰米·戴蒙 和“元”公司创始人扎克伯格等在内的10名美国富豪,就抛售了总价值达39亿美元的美股。另据美国彭博新闻社25日报道,美国高盛集团称,自3月初以来,外国投资者已经抛售了价值630亿美元的美国股票。(财联社)

2小时前

我国首台套商品化国产串列加速器研制成功

据中国原子能科学研究院报道,近日,中国原子能科学研究院为哈尔滨工程大学研制的串列加速器系统通过验收。这是国内首台套商品化串列加速器,标志着我国在串列加速器高端仪器设备制造领域取得重大突破,实现串列加速器的完全自主可控。(财联社)

2小时前

保时捷中国研发中心落户上海虹桥国际中央商务区

保时捷近日于2025上海国际车展正式宣布,其位于虹桥国际中央商务区嘉定片区的中国研发中心已完成战略性架构升级,全新投建的上海办公新址计划于今年下半年正式投入运营。

2小时前

教育部举办人工智能校长局长专题培训班

教育部举办人工智能校长局长专题培训班。教育部党组书记、部长怀进鹏强调,要优化知识体系,提升师生素养技能,加快建设人工智能课程体系、推进课程教材建设,全面提升教师的智能素养和育人本领。要深化平台应用,赋能教育改革创新,建强用好国家智慧教育平台,深入实施人工智能赋能教育行动,加快智能基础设施提档升级。

2小时前

本页详细列出关于来利Larlly的品牌信息,含品牌所属公司介绍,来利Larlly所处行业的品牌地位及优势。
咨询